BACKGROUND: Bariatric surgery can resolve type 2 diabetes in morbidly obese patients. However, the underlying mechanism is unknown. This study aimed to identify potential biomarkers or molecular pathways that are altered after bariatric surgery in diabetic and nondiabetic patients. METHODS: The study enrolled 17 morbidly obese patients undergoing bariatric surgery. Eight of the patients were diabetic, and nine were nondiabetic. In addition, a control group of four nonobese, nondiabetic volunteers was included. Patient blood samples were drawn before and after the operation. All blood samples were stabilized in Paxgene tubes (PreAnalytix). Total RNA was extracted and purified using the Paxgene Blood RNA Kit. For each sample, 100 ng of total RNA was amplified and labeled using the Ovation RNA Amplification System V2 with the Ovation Whole Blood reagent before hybridization to an Affymetrix Focus array containing more than 8,500 verified genes. Microarray results were analyzed with the GeneSpring GX 10.0 program, which uses an analysis of variance (ANOVA), and verified with real-time quantitative polymerase chain reaction (QPCR) using SYBR green (ABI). RESULTS: Microarray analysis showed that 167 genes were upregulated and 39 were downregulated in the obese diabetic patients. Preoperatively, adiponectin was downregulated 1.5-fold in diabetic versus nondiabetic patients. This was confirmed with quantitative PCR analysis. Preoperatively, morbidly obese patients showed a 3.12-fold downregulation of adiponectin expression versus the control group (p = 0.05). Interestingly, postoperative adiponectin levels were upregulated 2.79-fold (p = 0.02), which is close to the level of the normal control group. CONCLUSIONS: Adiponectin is dysregulated in obese patients and significantly dysregulated in obese diabetic patients. These findings correlate with the association between low levels of adiponectin and a predisposition to insulin resistance or diabetes. The data suggest that reactivation of adiponectin expression may play a part in the resolution of type 2 diabetes after bariatric surgery. Therefore, targeting adiponectin may help to develop alternative treatments for diabetes.
BACKGROUND: Bariatric surgery can resolve type 2 diabetes in morbidly obesepatients. However, the underlying mechanism is unknown. This study aimed to identify potential biomarkers or molecular pathways that are altered after bariatric surgery in diabetic and nondiabetic patients. METHODS: The study enrolled 17 morbidly obesepatients undergoing bariatric surgery. Eight of the patients were diabetic, and nine were nondiabetic. In addition, a control group of four nonobese, nondiabetic volunteers was included. Patient blood samples were drawn before and after the operation. All blood samples were stabilized in Paxgene tubes (PreAnalytix). Total RNA was extracted and purified using the Paxgene Blood RNA Kit. For each sample, 100 ng of total RNA was amplified and labeled using the Ovation RNA Amplification System V2 with the Ovation Whole Blood reagent before hybridization to an Affymetrix Focus array containing more than 8,500 verified genes. Microarray results were analyzed with the GeneSpring GX 10.0 program, which uses an analysis of variance (ANOVA), and verified with real-time quantitative polymerase chain reaction (QPCR) using SYBR green (ABI). RESULTS: Microarray analysis showed that 167 genes were upregulated and 39 were downregulated in the obese diabeticpatients. Preoperatively, adiponectin was downregulated 1.5-fold in diabetic versus nondiabeticpatients. This was confirmed with quantitative PCR analysis. Preoperatively, morbidly obesepatients showed a 3.12-fold downregulation of adiponectin expression versus the control group (p = 0.05). Interestingly, postoperative adiponectin levels were upregulated 2.79-fold (p = 0.02), which is close to the level of the normal control group. CONCLUSIONS:Adiponectin is dysregulated in obesepatients and significantly dysregulated in obese diabeticpatients. These findings correlate with the association between low levels of adiponectin and a predisposition to insulin resistance or diabetes. The data suggest that reactivation of adiponectin expression may play a part in the resolution of type 2 diabetes after bariatric surgery. Therefore, targeting adiponectin may help to develop alternative treatments for diabetes.
Authors: Ali H Mokdad; Earl S Ford; Barbara A Bowman; William H Dietz; Frank Vinicor; Virginia S Bales; James S Marks Journal: JAMA Date: 2003-01-01 Impact factor: 56.272
Authors: Lars Sjöström; Anna-Karin Lindroos; Markku Peltonen; Jarl Torgerson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Bo Larsson; Kristina Narbro; Carl David Sjöström; Marianne Sullivan; Hans Wedel Journal: N Engl J Med Date: 2004-12-23 Impact factor: 91.245
Authors: Marieke B Snijder; Robert J Heine; Jacob C Seidell; Lex M Bouter; Coen D A Stehouwer; Giel Nijpels; Tohru Funahashi; Yuji Matsuzawa; Iichiro Shimomura; Jacqueline M Dekker Journal: Diabetes Care Date: 2006-11 Impact factor: 19.112
Authors: Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal Journal: JAMA Date: 2006-04-05 Impact factor: 56.272
Authors: Vamsi K Mootha; Cecilia M Lindgren; Karl-Fredrik Eriksson; Aravind Subramanian; Smita Sihag; Joseph Lehar; Pere Puigserver; Emma Carlsson; Martin Ridderstråle; Esa Laurila; Nicholas Houstis; Mark J Daly; Nick Patterson; Jill P Mesirov; Todd R Golub; Pablo Tamayo; Bruce Spiegelman; Eric S Lander; Joel N Hirschhorn; David Altshuler; Leif C Groop Journal: Nat Genet Date: 2003-07 Impact factor: 38.330
Authors: Roby Joehanes; Andrew D Johnson; Jennifer J Barb; Nalini Raghavachari; Poching Liu; Kimberly A Woodhouse; Christopher J O'Donnell; Peter J Munson; Daniel Levy Journal: Physiol Genomics Date: 2011-11-01 Impact factor: 3.107
Authors: T Sledzinski; J Korczynska; A Hallmann; L Kaska; M Proczko-Markuszewska; T Stefaniak; M Sledzinski; J Swierczynski Journal: J Endocrinol Invest Date: 2012-11-27 Impact factor: 4.256
Authors: Pilar Cobeta; Roberto Pariente; Alvaro Osorio; Marta Marchan; Marta Cuadrado-Ayuso; David Pestaña; Julio Galindo; José I Botella-Carretero Journal: Biomedicines Date: 2022-08-17
Authors: Miguel Klünder-Klünder; Samuel Flores-Huerta; Rebeca García-Macedo; Jesús Peralta-Romero; Miguel Cruz Journal: BMC Public Health Date: 2013-01-30 Impact factor: 3.295
Authors: Jun Yang; Norma Diaz; Joseph Adelsberger; Xueyuan Zhou; Randy Stevens; Adam Rupert; Julia A Metcalf; Mike Baseler; Christine Barbon; Tomozumi Imamichi; Richard Lempicki; Louis M Cosentino Journal: BMC Immunol Date: 2016-03-15 Impact factor: 3.615